Search

Your search keyword '"Salles, P."' showing total 831 results
Start Over Author "Salles, P." Journal blood
831 results on '"Salles, P."'

1. Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume

Author

Locke, Frederick L., Oluwole, Olalekan O., Kuruvilla, John, Thieblemont, Catherine, Morschhauser, Franck, Salles, Gilles, Rowe, Steven P., Vardhanabhuti, Saran, Winters, Joshua, Filosto, Simone, To, Christina, Cheng, Paul, Schupp, Marco, Korn, Ronald, and Kersten, Marie José

Abstract

•MTV affected outcomes of second-line treatment in both arms, and axi-cel improved EFS and PFS over standard care, irrespective of MTV.•Baseline MTV associated with grade ≥3 CRS and neurologic events after axi-cel treatment.

Published
2024
Full Text
View/download PDF

2. BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1

Author

Delage, Lorric, Lambert, Mireille, Bardel, Émilie, Kundlacz, Cindy, Chartoire, Dimitri, Conchon, Axel, Peugnet, Anne-Laure, Gorka, Lucas, Auberger, Patrick, Jacquel, Arnaud, Soussain, Carole, Destaing, Olivier, Delecluse, Henri-Jacques, Delecluse, Susanne, Merabet, Samir, Traverse-Glehen, Alexandra, Salles, Gilles, Bachy, Emmanuel, Billaud, Marc, Ghesquières, Hervé, Genestier, Laurent, Rouault, Jean-Pierre, and Sujobert, Pierre

Abstract

Understanding the functional role of mutated genes in cancer is required to translate the findings of cancer genomics into therapeutic improvement. BTG1 is recurrently mutated in the MCD/C5 subtype of diffuse large B-cell lymphoma (DLBCL), which is associated with extranodal dissemination. Here, we provide evidence that Btg1 knock out accelerates the development of a lethal lymphoproliferative disease driven by Bcl2 overexpression. Furthermore, we show that the scaffolding protein BCAR1 is a BTG1 partner. Moreover, after BTG1 deletion or expression of BTG1 mutations observed in patients with DLBCL, the overactivation of the BCAR1-RAC1 pathway confers increased migration ability in vitro and in vivo. These modifications are targetable with the SRC inhibitor dasatinib, which opens novel therapeutic opportunities in BTG1 mutated DLBCL.

Published
2023
Full Text
View/download PDF

3. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities

Author

Falchi, Lorenzo, Vardhana, Santosha A., and Salles, Gilles A.

Abstract

Treatment paradigms for B-cell non-Hodgkin lymphomas (B-NHL) have shifted dramatically in the last 2 decades following the introduction of highly active immunotherapies such as rituximab. Since then, the field has continued to witness tremendous progress with the introduction of newer, more potent immunotherapeutics, including chimeric antigen receptor T-cell therapy, which have received regulatory approval for and currently play a significant role in the treatment of these diseases. Bispecific antibodies (BsAb) are a novel class of off-the-shelf T-cell redirecting drugs and are among the most promising immunotherapeutics for lymphoma today. BsAb may target various cell-surface antigens and exist in different formats. Anti-CD20xCD3 BsAb have demonstrated remarkable single-agent activity in patients with heavily pretreated B-NHL with a manageable toxicity profile dominated by T-cell overactivation syndromes. Much work remains to be done to define the optimal setting in which to deploy these drugs for B-NHL treatment, their ideal combination partners, strategies to minimize toxicity, and, perhaps most importantly, pharmacodynamic biomarkers of response and resistance. In this review, we provide an update on BsAb development in B-NHL, from discovery to clinical applications, highlighting the achievements, limitations, and future directions of the field.

Published
2023
Full Text
View/download PDF

5. Genomic profiling for clinical decision making in lymphoid neoplasms

Author

de Leval, Laurence, Alizadeh, Ash A., Bergsagel, P. Leif, Campo, Elias, Davies, Andrew, Dogan, Ahmet, Fitzgibbon, Jude, Horwitz, Steven M., Melnick, Ari M., Morice, William G., Morin, Ryan D., Nadel, Bertrand, Pileri, Stefano A., Rosenquist, Richard, Rossi, Davide, Salaverria, Itziar, Steidl, Christian, Treon, Steven P., Zelenetz, Andrew D., Advani, Ranjana H., Allen, Carl E., Ansell, Stephen M., Chan, Wing C., Cook, James R., Cook, Lucy B., d’Amore, Francesco, Dirnhofer, Stefan, Dreyling, Martin, Dunleavy, Kieron, Feldman, Andrew L., Fend, Falko, Gaulard, Philippe, Ghia, Paolo, Gribben, John G., Hermine, Olivier, Hodson, Daniel J., Hsi, Eric D., Inghirami, Giorgio, Jaffe, Elaine S., Karube, Kennosuke, Kataoka, Keisuke, Klapper, Wolfram, Kim, Won Seog, King, Rebecca L., Ko, Young H., LaCasce, Ann S., Lenz, Georg, Martin-Subero, José I., Piris, Miguel A., Pittaluga, Stefania, Pasqualucci, Laura, Quintanilla-Martinez, Leticia, Rodig, Scott J., Rosenwald, Andreas, Salles, Gilles A., San-Miguel, Jesus, Savage, Kerry J., Sehn, Laurie H., Semenzato, Gianpietro, Staudt, Louis M., Swerdlow, Steven H., Tam, Constantine S., Trotman, Judith, Vose, Julie M., Weigert, Oliver, Wilson, Wyndham H., Winter, Jane N., Wu, Catherine J., Zinzani, Pier L., Zucca, Emanuele, Bagg, Adam, and Scott, David W.

Abstract

With the introduction of large-scale molecular profiling methods and high-throughput sequencing technologies, the genomic features of most lymphoid neoplasms have been characterized at an unprecedented scale. Although the principles for the classification and diagnosis of these disorders, founded on a multidimensional definition of disease entities, have been consolidated over the past 25 years, novel genomic data have markedly enhanced our understanding of lymphomagenesis and enriched the description of disease entities at the molecular level. Yet, the current diagnosis of lymphoid tumors is largely based on morphological assessment and immunophenotyping, with only few entities being defined by genomic criteria. This paper, which accompanies the International Consensus Classification of mature lymphoid neoplasms, will address how established assays and newly developed technologies for molecular testing already complement clinical diagnoses and provide a novel lens on disease classification. More specifically, their contributions to diagnosis refinement, risk stratification, and therapy prediction will be considered for the main categories of lymphoid neoplasms. The potential of whole-genome sequencing, circulating tumor DNA analyses, single-cell analyses, and epigenetic profiling will be discussed because these will likely become important future tools for implementing precision medicine approaches in clinical decision making for patients with lymphoid malignancies.

Published
2022
Full Text
View/download PDF

6. Genomic profiling for clinical decision making in lymphoid neoplasms

Author

de Leval, Laurence, Alizadeh, Ash A., Bergsagel, P. Leif, Campo, Elias, Davies, Andrew, Dogan, Ahmet, Fitzgibbon, Jude, Horwitz, Steven M., Melnick, Ari M., Morice, William G., Morin, Ryan D., Nadel, Bertrand, Pileri, Stefano A., Rosenquist, Richard, Rossi, Davide, Salaverria, Itziar, Steidl, Christian, Treon, Steven P., Zelenetz, Andrew D., Advani, Ranjana H., Allen, Carl E., Ansell, Stephen M., Chan, Wing C., Cook, James R., Cook, Lucy B., d’Amore, Francesco, Dirnhofer, Stefan, Dreyling, Martin, Dunleavy, Kieron, Feldman, Andrew L., Fend, Falko, Gaulard, Philippe, Ghia, Paolo, Gribben, John G., Hermine, Olivier, Hodson, Daniel J., Hsi, Eric D., Inghirami, Giorgio, Jaffe, Elaine S., Karube, Kennosuke, Kataoka, Keisuke, Klapper, Wolfram, Kim, Won Seog, King, Rebecca L., Ko, Young H., LaCasce, Ann S., Lenz, Georg, Martin-Subero, José I., Piris, Miguel A., Pittaluga, Stefania, Pasqualucci, Laura, Quintanilla-Martinez, Leticia, Rodig, Scott J., Rosenwald, Andreas, Salles, Gilles A., San-Miguel, Jesus, Savage, Kerry J., Sehn, Laurie H., Semenzato, Gianpietro, Staudt, Louis M., Swerdlow, Steven H., Tam, Constantine S., Trotman, Judith, Vose, Julie M., Weigert, Oliver, Wilson, Wyndham H., Winter, Jane N., Wu, Catherine J., Zinzani, Pier L., Zucca, Emanuele, Bagg, Adam, and Scott, David W.

Abstract

With the introduction of large-scale molecular profiling methods and high-throughput sequencing technologies, the genomic features of most lymphoid neoplasms have been characterized at an unprecedented scale. Although the principles for the classification and diagnosis of these disorders, founded on a multidimensional definition of disease entities, have been consolidated over the past 25 years, novel genomic data have markedly enhanced our understanding of lymphomagenesis and enriched the description of disease entities at the molecular level. Yet, the current diagnosis of lymphoid tumors is largely based on morphological assessment and immunophenotyping, with only few entities being defined by genomic criteria. This paper, which accompanies the International Consensus Classification of mature lymphoid neoplasms, will address how established assays and newly developed technologies for molecular testing already complement clinical diagnoses and provide a novel lens on disease classification. More specifically, their contributions to diagnosis refinement, risk stratification, and therapy prediction will be considered for the main categories of lymphoid neoplasms. The potential of whole-genome sequencing, circulating tumor DNA analyses, single-cell analyses, and epigenetic profiling will be discussed because these will likely become important future tools for implementing precision medicine approaches in clinical decision making for patients with lymphoid malignancies.

Published
2022
Full Text
View/download PDF

7. A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

Author

Hess, Georg, Dreyling, Martin, Oberic, Lucie, Gine, Eva, Zinzani, Pier Luigi, Linton, Kim M., Vilmar, Adam, Jerkeman, Mats, Chen, Jenny MH, Ohler, Anke, Stilgenbauer, Stephan, Thieblemont, Catherine, Lambert, Jonathan, Zilioli, Vittorio Ruggero, Sancho, Juan-Manuel, Jimenez-Ubieto, Ana, Fischer, Luca, Eyre, Toby A., Keeping, Sam, Park, Julie E, Wu, James J, Siddiqi, Rubina, Reitan, John, Castaigne, Gab, and Salles, Gilles

Published
2022
Full Text
View/download PDF

8. Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study

Author

Sehn, Laurie H., Hertzberg, Mark, Opat, Stephen, Herrera, Alex F., Assouline, Sarit, Flowers, Christopher R., Kim, Tae Min, McMillan, Andrew K., Özcan, Muhit, Safar, Violaine, Salles, Gilles, Hirata, Jamie, Yang, Annie, Musick, Lisa, and Matasar, Matthew J.

Published
2022
Full Text
View/download PDF

9. Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study

Author

Sehn, Laurie H., Hertzberg, Mark, Opat, Stephen, Herrera, Alex F., Assouline, Sarit, Flowers, Christopher R., Kim, Tae Min, McMillan, Andrew K., Özcan, Muhit, Safar, Violaine, Salles, Gilles, Hirata, Jamie, Yang, Annie, Musick, Lisa, and Matasar, Matthew J.

Published
2022
Full Text
View/download PDF

10. Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study

Author

Friedberg, Jonathan W., Thompson, Carrie A., Trněný, Marek, Morschhauser, Franck, Salles, Gilles, Reagan, Patrick M., Hertzberg, Mark, Smolewski, Piotr, Zhang, Huilai, Thieblemont, Catherine, Hu, Bei, Fonseca, Gustavo, Kim, Won-Seog, Martelli, Maurizio, Mehta, Amitkumar, Campinha-Bacote, Avrita, Yan, Mark, Hirata, Jamie, Sugidono, Matthew, Lee, Calvin, and Sharman, Jeff P.

Published
2022
Full Text
View/download PDF

11. Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study

Author

Herrera, Alex F., McCord, Ronald, Kimes, Patrick, Jardin, Fabrice, Lenz, Georg, Trneny, Marek, Flowers, Christopher R., Sehn, Laurie H., Salles, Gilles, Sharman, Jeff P., Tilly, Hervé, Friedberg, Jonathan W., Herbaux, Charles, Matasar, Matthew J., Haioun, Corinne, Tracy, Samuel, Hirata, Jamie, Lee, Calvin, Jiang, Yanwen, and Morschhauser, Franck

Published
2022
Full Text
View/download PDF

12. Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study

Author

Herrera, Alex F., McCord, Ronald, Kimes, Patrick, Jardin, Fabrice, Lenz, Georg, Trneny, Marek, Flowers, Christopher R., Sehn, Laurie H., Salles, Gilles, Sharman, Jeff P., Tilly, Hervé, Friedberg, Jonathan W., Herbaux, Charles, Matasar, Matthew J., Haioun, Corinne, Tracy, Samuel, Hirata, Jamie, Lee, Calvin, Jiang, Yanwen, and Morschhauser, Franck

Published
2022
Full Text
View/download PDF

13. Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study

Author

Friedberg, Jonathan W., Thompson, Carrie A., Trněný, Marek, Morschhauser, Franck, Salles, Gilles, Reagan, Patrick M., Hertzberg, Mark, Smolewski, Piotr, Zhang, Huilai, Thieblemont, Catherine, Hu, Bei, Fonseca, Gustavo, Kim, Won-Seog, Martelli, Maurizio, Mehta, Amitkumar, Campinha-Bacote, Avrita, Yan, Mark, Hirata, Jamie, Sugidono, Matthew, Lee, Calvin, and Sharman, Jeff P.

Published
2022
Full Text
View/download PDF

14. A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

Author

Hess, Georg, Dreyling, Martin, Oberic, Lucie, Gine, Eva, Zinzani, Pier Luigi, Linton, Kim M., Vilmar, Adam, Jerkeman, Mats, Chen, Jenny MH, Ohler, Anke, Stilgenbauer, Stephan, Thieblemont, Catherine, Lambert, Jonathan, Zilioli, Vittorio Ruggero, Sancho, Juan-Manuel, Jimenez-Ubieto, Ana, Fischer, Luca, Eyre, Toby A., Keeping, Sam, Park, Julie E, Wu, James J, Siddiqi, Rubina, Reitan, John, Castaigne, Gab, and Salles, Gilles

Published
2022
Full Text
View/download PDF

15. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Author

Campo, Elias, Jaffe, Elaine S., Cook, James R., Quintanilla-Martinez, Leticia, Swerdlow, Steven H., Anderson, Kenneth C., Brousset, Pierre, Cerroni, Lorenzo, de Leval, Laurence, Dirnhofer, Stefan, Dogan, Ahmet, Feldman, Andrew L., Fend, Falko, Friedberg, Jonathan W., Gaulard, Philippe, Ghia, Paolo, Horwitz, Steven M., King, Rebecca L., Salles, Gilles, San-Miguel, Jesus, Seymour, John F., Treon, Steven P., Vose, Julie M., Zucca, Emanuele, Advani, Ranjana, Ansell, Stephen, Au, Wing-Yan, Barrionuevo, Carlos, Bergsagel, Leif, Chan, Wing C., Cohen, Jeffrey I., d’Amore, Francesco, Davies, Andrew, Falini, Brunangelo, Ghobrial, Irene M., Goodlad, John R., Gribben, John G., Hsi, Eric D., Kahl, Brad S., Kim, Won-Seog, Kumar, Shaji, LaCasce, Ann S., Laurent, Camille, Lenz, Georg, Leonard, John P., Link, Michael P., Lopez-Guillermo, Armando, Mateos, Maria Victoria, Macintyre, Elizabeth, Melnick, Ari M., Morschhauser, Franck, Nakamura, Shigeo, Narbaitz, Marina, Pavlovsky, Astrid, Pileri, Stefano A., Piris, Miguel, Pro, Barbara, Rajkumar, Vincent, Rosen, Steven T., Sander, Birgitta, Sehn, Laurie, Shipp, Margaret A., Smith, Sonali M., Staudt, Louis M., Thieblemont, Catherine, Tousseyn, Thomas, Wilson, Wyndham H., Yoshino, Tadashi, Zinzani, Pier-Luigi, Dreyling, Martin, Scott, David W., Winter, Jane N., and Zelenetz, Andrew D.

Abstract

Since the publication of the Revised European-American Classification of Lymphoid Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have been generated through iterative international efforts to achieve broad consensus among hematopathologists, geneticists, molecular scientists, and clinicians. Significant progress has recently been made in the characterization of malignancies of the immune system, with many new insights provided by genomic studies. They have led to this proposal. We have followed the same process that was successfully used for the third and fourth editions of the World Health Organization Classification of Hematologic Neoplasms. The definition, recommended studies, and criteria for the diagnosis of many entities have been extensively refined. Some categories considered provisional have now been upgraded to definite entities. Terminology for some diseases has been revised to adapt nomenclature to the current knowledge of their biology, but these modifications have been restricted to well-justified situations. Major findings from recent genomic studies have impacted the conceptual framework and diagnostic criteria for many disease entities. These changes will have an impact on optimal clinical management. The conclusions of this work are summarized in this report as the proposed International Consensus Classification of mature lymphoid, histiocytic, and dendritic cell tumors.

Published
2022
Full Text
View/download PDF

16. Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study

Author

Bachy, Emmanuel, Houot, Roch, Feugier, Pierre, Bouabdallah, Krimo, Bouabdallah, Reda, Virelizier, Emmanuelle Nicolas, Maerevoet, Marie, Fruchart, Christophe, Snauwaert, Sylvia, Le Gouill, Steven, Marolleau, Jean-Pierre, Molina, Lysiane, Moluçon-Chabrot, Cécile, Thieblemont, Catherine, Tilly, Hervé, Bijou, Fontanet, Haioun, Corinne, Van den Neste, Eric, Fabiani, Bettina, Meignan, Michel, Cartron, Guillaume, Salles, Gilles, Casasnovas, Olivier, and Morschhauser, Franck

Abstract

Obinutuzumab and lenalidomide (referred to as the GALEN combination) is an active immunomodulatory combination with a manageable safety profile in multiple types of lymphoma. We report efficacy and safety results for the phase 2 GALEN study in previously untreated patients with advanced follicular lymphoma (FL). Eligible patients aged ≥18 years had an Eastern Cooperative Oncology Group performance status ≤2 and high-tumor burden, grade 1 to 3a FL. Induction treatment was obinutuzumab (1000 mg IV, days 8, 15, and 22, cycle 1; day 1, cycles 2-6) plus lenalidomide (20 mg/d, days 1-21, cycle 1; days 2-22, cycles 2-6) for six 28-day cycles. Maintenance included obinutuzumab (1000 mg every 2 cycles) plus lenalidomide (10 mg, days 2-22) for ≤12 cycles (year 1) followed by obinutuzumab (1000 mg every 56 days) for 6 cycles (year 2). The primary end point was complete response rate (CRR) after induction per the 1999 International Working Group criteria. From October 2015 to February 2017, a total of 100 patients were enrolled. CRR after induction was 47%, and the overall response rate (ORR) was 92%. Post hoc analyses per the 2014 Lugano classification, including patients with missing bone marrow assessments, identified an additional 13 patients fulfilling CRR criteria, resulting in a complete metabolic response of 80% and an ORR of 94%. At a median follow-up of 3.7 years, 3-year progression-free survival and overall survival were 82% and 94%, respectively. The most common adverse event was neutropenia (48% any grade; 47% grade ≥3). Only 2% of patients presented with febrile neutropenia; others were mainly grade ≤2. No other specific grade ≥3 toxicity occurred at a frequency >3%. Overall, these results showed promising clinical efficacy for the chemotherapy-free GALEN backbone in previously untreated patients with high tumor burden FL. Except for neutropenia, the safety profile of the combination is remarkable. The study was registered at clinicaltrials.gov as #NCT01582776.

Published
2022
Full Text
View/download PDF

17. Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study

Author

Bachy, Emmanuel, Houot, Roch, Feugier, Pierre, Bouabdallah, Krimo, Bouabdallah, Reda, Virelizier, Emmanuelle Nicolas, Maerevoet, Marie, Fruchart, Christophe, Snauwaert, Sylvia, Le Gouill, Steven, Marolleau, Jean-Pierre, Molina, Lysiane, Moluçon-Chabrot, Cécile, Thieblemont, Catherine, Tilly, Hervé, Bijou, Fontanet, Haioun, Corinne, Van den Neste, Eric, Fabiani, Bettina, Meignan, Michel, Cartron, Guillaume, Salles, Gilles, Casasnovas, Olivier, and Morschhauser, Franck

Abstract

Obinutuzumab and lenalidomide (referred to as the GALEN combination) is an active immunomodulatory combination with a manageable safety profile in multiple types of lymphoma. We report efficacy and safety results for the phase 2 GALEN study in previously untreated patients with advanced follicular lymphoma (FL). Eligible patients aged ≥18 years had an Eastern Cooperative Oncology Group performance status ≤2 and high-tumor burden, grade 1 to 3a FL. Induction treatment was obinutuzumab (1000 mg IV, days 8, 15, and 22, cycle 1; day 1, cycles 2-6) plus lenalidomide (20 mg/d, days 1-21, cycle 1; days 2-22, cycles 2-6) for six 28-day cycles. Maintenance included obinutuzumab (1000 mg every 2 cycles) plus lenalidomide (10 mg, days 2-22) for ≤12 cycles (year 1) followed by obinutuzumab (1000 mg every 56 days) for 6 cycles (year 2). The primary end point was complete response rate (CRR) after induction per the 1999 International Working Group criteria. From October 2015 to February 2017, a total of 100 patients were enrolled. CRR after induction was 47%, and the overall response rate (ORR) was 92%. Post hoc analyses per the 2014 Lugano classification, including patients with missing bone marrow assessments, identified an additional 13 patients fulfilling CRR criteria, resulting in a complete metabolic response of 80% and an ORR of 94%. At a median follow-up of 3.7 years, 3-year progression-free survival and overall survival were 82% and 94%, respectively. The most common adverse event was neutropenia (48% any grade; 47% grade ≥3). Only 2% of patients presented with febrile neutropenia; others were mainly grade ≤2. No other specific grade ≥3 toxicity occurred at a frequency >3%. Overall, these results showed promising clinical efficacy for the chemotherapy-free GALEN backbone in previously untreated patients with high tumor burden FL. Except for neutropenia, the safety profile of the combination is remarkable. The study was registered at clinicaltrials.gov as #NCT01582776.

Published
2022
Full Text
View/download PDF

18. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials

Author

Casulo, Carla, Dixon, Jesse G., Le-Rademacher, Jennifer, Hoster, Eva, Hochster, Howard S., Hiddemann, Wolfgang, Marcus, Robert, Kimby, Eva, Herold, Michael, Sebban, Catherine, Gyan, Emmanuel, Foon, Kenneth, Nielsen, Tina, Vitolo, Umberto, Salles, Gilles A., Shi, Qian, and Flowers, Christopher R.

Abstract

Observational studies and stand-alone trials indicate that patients with follicular lymphoma (FL) who experience disease progression within 24 months of front-line chemoimmunotherapy (POD24), have poor outcomes. We performed a pooled analysis of 13 randomized clinical trials of patients with FL in the pre- and postrituximab eras to identify clinical factors that predict POD24. Logistic regression models evaluated the association between clinical factors and POD24. Cox regression evaluated the association between POD24 as a time-dependent factor and subsequent overall survival (OS). A landmark analysis evaluated the association of POD24 with OS for the subset of patients who were alive at 24 months after trial registration. Patients without progression at 24 months at baseline had favorable performance status (PS), limited-stage (I/II) disease, low-risk FL International Prognostic Index (FLIPI) score, normal baseline hemoglobin, and normal baseline β2 microglobulin (B2M) level. In a multivariable logistic regression model, male sex (odds ratio [OR], 1.30), PS ≥2 (OR, 1.63), B2M (≥3 mg/L; OR, 1.43), and high-risk FLIPI score (3-5; OR, 3.14) were associated with increased risk of progression before 24 months. In the time-dependent Cox model and the 24-month landmark analysis, POD24 was associated with poor subsequent OS (hazard ratio, 4.85 and 3.06, respectively). This is the largest pooled analysis of clinical trials data validating POD24 as a robust indicator of poor FL survival and identified clinical predictors of early death and progression that can aid in building comprehensive prognostic models incorporating clinical and molecular predictors of POD24.

Published
2022
Full Text
View/download PDF

19. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials

Author

Casulo, Carla, Dixon, Jesse G., Le-Rademacher, Jennifer, Hoster, Eva, Hochster, Howard S., Hiddemann, Wolfgang, Marcus, Robert, Kimby, Eva, Herold, Michael, Sebban, Catherine, Gyan, Emmanuel, Foon, Kenneth, Nielsen, Tina, Vitolo, Umberto, Salles, Gilles A., Shi, Qian, and Flowers, Christopher R.

Abstract

Observational studies and stand-alone trials indicate that patients with follicular lymphoma (FL) who experience disease progression within 24 months of front-line chemoimmunotherapy (POD24), have poor outcomes. We performed a pooled analysis of 13 randomized clinical trials of patients with FL in the pre- and postrituximab eras to identify clinical factors that predict POD24. Logistic regression models evaluated the association between clinical factors and POD24. Cox regression evaluated the association between POD24 as a time-dependent factor and subsequent overall survival (OS). A landmark analysis evaluated the association of POD24 with OS for the subset of patients who were alive at 24 months after trial registration. Patients without progression at 24 months at baseline had favorable performance status (PS), limited-stage (I/II) disease, low-risk FL International Prognostic Index (FLIPI) score, normal baseline hemoglobin, and normal baseline β2microglobulin (B2M) level. In a multivariable logistic regression model, male sex (odds ratio [OR], 1.30), PS ≥2 (OR, 1.63), B2M (≥3 mg/L; OR, 1.43), and high-risk FLIPI score (3-5; OR, 3.14) were associated with increased risk of progression before 24 months. In the time-dependent Cox model and the 24-month landmark analysis, POD24 was associated with poor subsequent OS (hazard ratio, 4.85 and 3.06, respectively). This is the largest pooled analysis of clinical trials data validating POD24 as a robust indicator of poor FL survival and identified clinical predictors of early death and progression that can aid in building comprehensive prognostic models incorporating clinical and molecular predictors of POD24.

Published
2022
Full Text
View/download PDF

20. Genetic and phenotypic attributes of splenic marginal zone lymphoma

Author

Bonfiglio, Ferdinando, Bruscaggin, Alessio, Guidetti, Francesca, Terzi di Bergamo, Lodovico, Faderl, Martin, Spina, Valeria, Condoluci, Adalgisa, Bonomini, Luisella, Forestieri, Gabriela, Koch, Ricardo, Piffaretti, Deborah, Pini, Katia, Pirosa, Maria Cristina, Cittone, Micol Giulia, Arribas, Alberto, Lucioni, Marco, Ghilardi, Guido, Wu, Wei, Arcaini, Luca, Baptista, Maria Joao, Bastidas, Gabriela, Bea, Silvia, Boldorini, Renzo, Broccoli, Alessandro, Buehler, Marco Matteo, Canzonieri, Vincenzo, Cascione, Luciano, Ceriani, Luca, Cogliatti, Sergio, Corradini, Paolo, Derenzini, Enrico, Devizzi, Liliana, Dietrich, Sascha, Elia, Angela Rita, Facchetti, Fabio, Gaidano, Gianluca, Garcia, Juan Fernando, Gerber, Bernhard, Ghia, Paolo, Gomes da Silva, Maria, Gritti, Giuseppe, Guidetti, Anna, Hitz, Felicitas, Inghirami, Giorgio, Ladetto, Marco, Lopez-Guillermo, Armando, Lucchini, Elisa, Maiorana, Antonino, Marasca, Roberto, Matutes, Estella, Meignin, Veronique, Merli, Michele, Moccia, Alden, Mollejo, Manuela, Montalban, Carlos, Novak, Urban, Oscier, David Graham, Passamonti, Francesco, Piazza, Francesco, Pizzolitto, Stefano, Rambaldi, Alessandro, Sabattini, Elena, Salles, Gilles, Santambrogio, Elisa, Scarfò, Lydia, Stathis, Anastasios, Stüssi, Georg, Geyer, Julia T., Tapia, Gustavo, Tarella, Corrado, Thieblemont, Catherine, Tousseyn, Thomas, Tucci, Alessandra, Vanini, Giorgio, Visco, Carlo, Vitolo, Umberto, Walewska, Renata, Zaja, Francesco, Zenz, Thorsten, Zinzani, Pier Luigi, Khiabanian, Hossein, Calcinotto, Arianna, Bertoni, Francesco, Bhagat, Govind, Campo, Elias, De Leval, Laurence, Dirnhofer, Stefan, Pileri, Stefano A., Piris, Miguel A., Traverse-Glehen, Alexandra, Tzankov, Alexander, Paulli, Marco, Ponzoni, Maurilio, Mazzucchelli, Luca, Cavalli, Franco, Zucca, Emanuele, and Rossi, Davide

Abstract

Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity. The clinical course is variable, multiple genes are mutated with no unifying mechanism, and essential regulatory pathways and surrounding microenvironments are diverse. We sought to clarify the heterogeneity of SMZL by resolving different subgroups and their underlying genomic abnormalities, pathway signatures, and microenvironment compositions to uncover biomarkers and therapeutic vulnerabilities. We studied 303 SMZL spleen samples collected through the IELSG46 multicenter international study (NCT02945319) by using a multiplatform approach. We carried out genetic and phenotypic analyses, defined self-organized signatures, validated the findings in independent primary tumor metadata and determined correlations with outcome data. We identified 2 prominent genetic clusters in SMZL, termed NNK (58% of cases, harboring NF-κB, NOTCH, and KLF2 modules) and DMT (32% of cases, with DNA-damage response, MAPK, and TLR modules). Genetic aberrations in multiple genes as well as cytogenetic and immunogenetic features distinguished NNK- from DMT-SMZLs. These genetic clusters not only have distinct underpinning biology, as judged by differences in gene-expression signatures, but also different outcomes, with inferior survival in NNK-SMZLs. Digital cytometry and in situ profiling segregated 2 basic types of SMZL immune microenvironments termed immune-suppressive SMZL (50% of cases, associated with inflammatory cells and immune checkpoint activation) and immune-silent SMZL (50% of cases, associated with an immune-excluded phenotype) with distinct mutational and clinical connotations. In summary, we propose a nosology of SMZL that can implement its classification and also aid in the development of rationally targeted treatments.

Published
2022
Full Text
View/download PDF

21. Genetic and phenotypic attributes of splenic marginal zone lymphoma

Author

Bonfiglio, Ferdinando, Bruscaggin, Alessio, Guidetti, Francesca, Terzi di Bergamo, Lodovico, Faderl, Martin, Spina, Valeria, Condoluci, Adalgisa, Bonomini, Luisella, Forestieri, Gabriela, Koch, Ricardo, Piffaretti, Deborah, Pini, Katia, Pirosa, Maria Cristina, Cittone, Micol Giulia, Arribas, Alberto, Lucioni, Marco, Ghilardi, Guido, Wu, Wei, Arcaini, Luca, Baptista, Maria Joao, Bastidas, Gabriela, Bea, Silvia, Boldorini, Renzo, Broccoli, Alessandro, Buehler, Marco Matteo, Canzonieri, Vincenzo, Cascione, Luciano, Ceriani, Luca, Cogliatti, Sergio, Corradini, Paolo, Derenzini, Enrico, Devizzi, Liliana, Dietrich, Sascha, Elia, Angela Rita, Facchetti, Fabio, Gaidano, Gianluca, Garcia, Juan Fernando, Gerber, Bernhard, Ghia, Paolo, Gomes da Silva, Maria, Gritti, Giuseppe, Guidetti, Anna, Hitz, Felicitas, Inghirami, Giorgio, Ladetto, Marco, Lopez-Guillermo, Armando, Lucchini, Elisa, Maiorana, Antonino, Marasca, Roberto, Matutes, Estella, Meignin, Veronique, Merli, Michele, Moccia, Alden, Mollejo, Manuela, Montalban, Carlos, Novak, Urban, Oscier, David Graham, Passamonti, Francesco, Piazza, Francesco, Pizzolitto, Stefano, Rambaldi, Alessandro, Sabattini, Elena, Salles, Gilles, Santambrogio, Elisa, Scarfò, Lydia, Stathis, Anastasios, Stüssi, Georg, Geyer, Julia T., Tapia, Gustavo, Tarella, Corrado, Thieblemont, Catherine, Tousseyn, Thomas, Tucci, Alessandra, Vanini, Giorgio, Visco, Carlo, Vitolo, Umberto, Walewska, Renata, Zaja, Francesco, Zenz, Thorsten, Zinzani, Pier Luigi, Khiabanian, Hossein, Calcinotto, Arianna, Bertoni, Francesco, Bhagat, Govind, Campo, Elias, De Leval, Laurence, Dirnhofer, Stefan, Pileri, Stefano A., Piris, Miguel A., Traverse-Glehen, Alexandra, Tzankov, Alexander, Paulli, Marco, Ponzoni, Maurilio, Mazzucchelli, Luca, Cavalli, Franco, Zucca, Emanuele, and Rossi, Davide

Abstract

Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity. The clinical course is variable, multiple genes are mutated with no unifying mechanism, and essential regulatory pathways and surrounding microenvironments are diverse. We sought to clarify the heterogeneity of SMZL by resolving different subgroups and their underlying genomic abnormalities, pathway signatures, and microenvironment compositions to uncover biomarkers and therapeutic vulnerabilities. We studied 303 SMZL spleen samples collected through the IELSG46 multicenter international study (NCT02945319) by using a multiplatform approach. We carried out genetic and phenotypic analyses, defined self-organized signatures, validated the findings in independent primary tumor metadata and determined correlations with outcome data. We identified 2 prominent genetic clusters in SMZL, termed NNK (58% of cases, harboring NF-κB, NOTCH, and KLF2modules) and DMT (32% of cases, with DNA-damage response, MAPK, and TLR modules). Genetic aberrations in multiple genes as well as cytogenetic and immunogenetic features distinguished NNK- from DMT-SMZLs. These genetic clusters not only have distinct underpinning biology, as judged by differences in gene-expression signatures, but also different outcomes, with inferior survival in NNK-SMZLs. Digital cytometry and in situ profiling segregated 2 basic types of SMZL immune microenvironments termed immune-suppressive SMZL (50% of cases, associated with inflammatory cells and immune checkpoint activation) and immune-silent SMZL (50% of cases, associated with an immune-excluded phenotype) with distinct mutational and clinical connotations. In summary, we propose a nosology of SMZL that can implement its classification and also aid in the development of rationally targeted treatments.

Published
2022
Full Text
View/download PDF

23. Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study

Author

Boissard, Frédéric, Tilly, Hervé, Lenz, Georg, Collins, Graham P., Pinto, Antonio, Sehn, Laurie H., Salles, Gilles, Roussel, Mathilde, Simonella, Leonardo, Ho, Rodrigo, Hirata, Jamie, Lee, Calvin, Masaquel, Anthony, and Launonen, Aino

Published
2022
Full Text
View/download PDF

24. Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation

Author

Stuver, Robert, Drill, Esther, Qualls, David, Okwali, Michelle, Batlevi, Connie Lee, Caron, Philip C, Epstein-Peterson, Zachary D., Falchi, Lorenzo, Hamilton, Audrey, Hamlin, Paul A., Horwitz, Steven M., Intlekofer, Andrew M., Johnson, William T., Khan, Niloufer, Lahoud, Oscar B, Lue, Jennifer Kimberly, Matasar, Matthew J., Moskowitz, Alison J., Noy, Ariela, Palomba, M.Lia, Vardhana, Santosha, Zelenetz, Andrew D., Salles, Gilles, and Straus, David J.

Published
2022
Full Text
View/download PDF

25. Outcome in Multiple Myeloma Patients Treated in the Era of Modern Therapies Who Were Admitted to Intensive Care: A Retrospective Analysis from a Teaching Hospital between 2014 and 2019

Author

Gross, Zofia, Idlhaj, Maryam, Karlin, Lionel, Friggeri, Arnaud, Lazareth, Anne, Golfier, Camille, Lequeu, Helene, Bouafia Sauvy, Fadhela, Sesques, Pierre, Safar, Violaine, Ferrant, Emmanuelle, Ghergus, Dana, Maarek, Alizee, Aussedat, Guillaume, Salles, Gilles, Bachy, Emmanuel, Wallet, Florent, and Ghesquieres, Herve

Published
2022
Full Text
View/download PDF

26. Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study

Author

Qualls, David, Buege, Michael J, Dao, Phuong, Caimi, Paolo F., Rutherford, Sarah C., Wehmeyer, Graham, Romancik, Jason T., Leslie, Lori A., Merrill, Mwanasha H., Crombie, Jennifer L., Amoozgar, Behzad, Kahl, Brad S., Bond, David A., Maddocks, Kami J., Okwali, Michelle, Seshan, Venkatraman, Salles, Gilles, and Batlevi, Connie Lee

Published
2022
Full Text
View/download PDF

27. Inflammatory Biomarker Clusters Are Predictive of Response and Toxicity in Large B-Cell Lymphoma Treated with CD19 CAR-T Cell Therapy

Author

Raj, Sandeep, Perales, Miguel-Angel, Fein, Joshua A, Alarcon Tomas, Ana, Batlevi, Connie Lee, Corona De Lapuerta, Magdalena, Dahi, Parastoo B, Danylesko, Ivetta, Fried, Shalev, Funnell, Tyler, Giralt, Sergio A., Jacoby, Elad, Kedmi, Meirav, Lin, Richard J., Nagler, Arnon, Nath, Karthik, Parascondola, Allison, Palomba, M.Lia, Salles, Gilles, Scordo, Michael, Shah, Gunjan L., Shem-Tov, Noga, Shimoni, Avichai, Slingerland, John, Walji, Moneeza, Yerushalmi, Ronit, Avigdor, Abraham, van den Brink, Marcel R M, and Shouval, Roni

Published
2022
Full Text
View/download PDF

28. Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Author

Wills, Beatriz, Ganesan, Nivetha, Shah, Gunjan L., Wong, Phillip, Argyropoulos, Kimon V., Sen, Filiz, Dogan, Ahmet, Straus, David J., Noy, Ariela, Kumar, Anita, Schoder, Heiko, Michaud, Laure, Palomba, Maria Lia, Falchi, Lorenzo, Lahoud, Oscar B, Hamlin, Paul A., Yahalom, Joachim, Johnson, William T., Zelenetz, Andrew D., Intlekofer, Andrew M., Owens, Colette, Batlevi, Connie Lee, Hamilton, Audrey, Caron, Philip C, Horwitz, Steven M., Galasso, Natasha, Hancock, Helen, Davey, Theresa, Santarosa, Alayna, Perez, Leslie, Capadona, Charisse, Munayirji, Brittney, Matasar, Matthew J., Pongas, Georgios, Casper, Ellie, Salles, Gilles, Moskowitz, Craig H., Vardhana, Santosha, and Moskowitz, Alison J.

Published
2022
Full Text
View/download PDF

30. Outcome in Multiple Myeloma Patients Treated in the Era of Modern Therapies Who Were Admitted to Intensive Care: A Retrospective Analysis from a Teaching Hospital between 2014 and 2019

Author

Gross, Zofia, Idlhaj, Maryam, Karlin, Lionel, Friggeri, Arnaud, Lazareth, Anne, Golfier, Camille, Lequeu, Helene, Bouafia Sauvy, Fadhela, Sesques, Pierre, Safar, Violaine, Ferrant, Emmanuelle, Ghergus, Dana, Maarek, Alizee, Aussedat, Guillaume, Salles, Gilles, Bachy, Emmanuel, Wallet, Florent, and Ghesquieres, Herve

Published
2022
Full Text
View/download PDF

32. Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study

Author

Boissard, Frédéric, Tilly, Hervé, Lenz, Georg, Collins, Graham P., Pinto, Antonio, Sehn, Laurie H., Salles, Gilles, Roussel, Mathilde, Simonella, Leonardo, Ho, Rodrigo, Hirata, Jamie, Lee, Calvin, Masaquel, Anthony, and Launonen, Aino

Published
2022
Full Text
View/download PDF

34. Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation

Author

Stuver, Robert, Drill, Esther, Qualls, David, Okwali, Michelle, Batlevi, Connie Lee, Caron, Philip C, Epstein-Peterson, Zachary D., Falchi, Lorenzo, Hamilton, Audrey, Hamlin, Paul A., Horwitz, Steven M., Intlekofer, Andrew M., Johnson, William T., Khan, Niloufer, Lahoud, Oscar B, Lue, Jennifer Kimberly, Matasar, Matthew J., Moskowitz, Alison J., Noy, Ariela, Palomba, M.Lia, Vardhana, Santosha, Zelenetz, Andrew D., Salles, Gilles, and Straus, David J.

Published
2022
Full Text
View/download PDF

35. Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study

Author

Qualls, David, Buege, Michael J, Dao, Phuong, Caimi, Paolo F., Rutherford, Sarah C., Wehmeyer, Graham, Romancik, Jason T., Leslie, Lori A., Merrill, Mwanasha H., Crombie, Jennifer L., Amoozgar, Behzad, Kahl, Brad S., Bond, David A., Maddocks, Kami J., Okwali, Michelle, Seshan, Venkatraman, Salles, Gilles, and Batlevi, Connie Lee

Published
2022
Full Text
View/download PDF

36. Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing

Author

Batlevi, Connie Lee, Drill, Esther, Okwali, Michelle, Ptashkin, Ryan, Caron, Philip C, Epstein-Peterson, Zachary D., Falchi, Lorenzo, Hamilton, Audrey, Hamlin, Paul A., Horwitz, Steven M., Intlekofer, Andrew M., Johnson, William T., Khan, Niloufer, Kumar, Anita, Lue, Jennifer Kimberly, Matasar, Matthew J., Moskowitz, Alison J., Noy, Ariela, Owens, Colette, Palomba, Maria Lia, Straus, David J., Vardhana, Santosha, Zelenetz, Andrew D., Arcila, Maria E., Dogan, Ahmet, Seshan, Venkatraman, Salles, Gilles, Zehir, Ahmet, and Younes, Anas

Published
2022
Full Text
View/download PDF

37. Correlative Biomarkers for CART19 Response in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Author

Batlevi, Connie Lee, Nos, Grigorii, Kotlov, Nikita, Sorokina, Maria, Okwali, Michelle, Bagaev, Alexander, Michaud, Laure, Shah, Gunjan L., Shouval, Roni, Alarcon Tomas, Ana, Ewalt, Mark D., Belova, Ekaterina, Degryse, Sandrine, Tazearslan, Cagdas, Podsvirova, Svetlana, Love, Anna Mooney, Postovalova, Ekaterina, Fowler, Nathan H., Perales, Miguel-Angel, Schoder, Heiko, Dogan, Ahmet, Arcila, Maria E., Salles, Gilles, and Sauter, Craig S.

Published
2022
Full Text
View/download PDF

38. Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results from the European MCL Elderly Trial

Author

Hoster, Eva, Delfau, Marie-Helene, Macintyre, Elizabeth A., Jiang, Linmiao, Stilgenbauer, Stephan, Vehling-Kaiser, Ursula, Salles, Gilles, Thieblemont, Catherine, Tilly, Hervé, Kanz, Lothar, Feugier, Pierre, Huebel, Kai, Schmidt, Christian, Ribrag, Vincent, Kluin-Nelemans, Hanneke, Dreyling, Martin, and Pott, Christiane

Published
2022
Full Text
View/download PDF

39. A Genome-Wide Association Study (GWAS) of Event-Free Survival (EFS) in Follicular Lymphoma Patients Treated with Front-Line Immunochemotherapy: A Lysa, Iowa/Mayo MER, and FIL Study

Author

Ghesquieres, Herve, Drouet, Youenn, Slager, Susan L., Morschhauser, Franck, Galimberti, Sara, Robinson, Dennis P., Thomas, Emilie, Novak, Anne J., Xerri, Luc, Luminari, Stefano, Verney, Aurelie, Laurent, Camille, Rimsza, Lisa M., Habermann, Thomas M., Federico, Massimo, Link, Brian K., Salles, Gilles, and Cerhan, James R.

Published
2022
Full Text
View/download PDF

41. Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Author

Wills, Beatriz, Ganesan, Nivetha, Shah, Gunjan L., Wong, Phillip, Argyropoulos, Kimon V., Sen, Filiz, Dogan, Ahmet, Straus, David J., Noy, Ariela, Kumar, Anita, Schoder, Heiko, Michaud, Laure, Palomba, Maria Lia, Falchi, Lorenzo, Lahoud, Oscar B, Hamlin, Paul A., Yahalom, Joachim, Johnson, William T., Zelenetz, Andrew D., Intlekofer, Andrew M., Owens, Colette, Batlevi, Connie Lee, Hamilton, Audrey, Caron, Philip C, Horwitz, Steven M., Galasso, Natasha, Hancock, Helen, Davey, Theresa, Santarosa, Alayna, Perez, Leslie, Capadona, Charisse, Munayirji, Brittney, Matasar, Matthew J., Pongas, Georgios, Casper, Ellie, Salles, Gilles, Moskowitz, Craig H., Vardhana, Santosha, and Moskowitz, Alison J.

Published
2022
Full Text
View/download PDF

42. Correlative Biomarkers for CART19 Response in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Author

Batlevi, Connie Lee, Nos, Grigorii, Kotlov, Nikita, Sorokina, Maria, Okwali, Michelle, Bagaev, Alexander, Michaud, Laure, Shah, Gunjan L., Shouval, Roni, Alarcon Tomas, Ana, Ewalt, Mark D., Belova, Ekaterina, Degryse, Sandrine, Tazearslan, Cagdas, Podsvirova, Svetlana, Love, Anna Mooney, Postovalova, Ekaterina, Fowler, Nathan H., Perales, Miguel-Angel, Schoder, Heiko, Dogan, Ahmet, Arcila, Maria E., Salles, Gilles, and Sauter, Craig S.

Published
2022
Full Text
View/download PDF

43. Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing

Author

Batlevi, Connie Lee, Drill, Esther, Okwali, Michelle, Ptashkin, Ryan, Caron, Philip C, Epstein-Peterson, Zachary D., Falchi, Lorenzo, Hamilton, Audrey, Hamlin, Paul A., Horwitz, Steven M., Intlekofer, Andrew M., Johnson, William T., Khan, Niloufer, Kumar, Anita, Lue, Jennifer Kimberly, Matasar, Matthew J., Moskowitz, Alison J., Noy, Ariela, Owens, Colette, Palomba, Maria Lia, Straus, David J., Vardhana, Santosha, Zelenetz, Andrew D., Arcila, Maria E., Dogan, Ahmet, Seshan, Venkatraman, Salles, Gilles, Zehir, Ahmet, and Younes, Anas

Published
2022
Full Text
View/download PDF

44. Association of Metabolic Tumor Volume (MTV) and Clinical Outcomes in Second-Line (2L) Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in ZUMA-7

Author

Locke, Frederick L., Oluwole, Olalekan O., Kuruvilla, John, Thieblemont, Catherine, Morschhauser, Franck, Salles, Gilles, Rowe, Steven P, Vardhanabhuti, Saran, Filosto, Simone, To, Christina, Cheng, Paul, Schupp, Marco, Korn, Ronald, and Kersten, Marie José

Published
2022
Full Text
View/download PDF

47. A Genome-Wide Association Study (GWAS) of Event-Free Survival (EFS) in Follicular Lymphoma Patients Treated with Front-Line Immunochemotherapy: A Lysa, Iowa/Mayo MER, and FIL Study

Author

Ghesquieres, Herve, Drouet, Youenn, Slager, Susan L., Morschhauser, Franck, Galimberti, Sara, Robinson, Dennis P., Thomas, Emilie, Novak, Anne J., Xerri, Luc, Luminari, Stefano, Verney, Aurelie, Laurent, Camille, Rimsza, Lisa M., Habermann, Thomas M., Federico, Massimo, Link, Brian K., Salles, Gilles, and Cerhan, James R.

Published
2022
Full Text
View/download PDF

50. Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results from the European MCL Elderly Trial

Author

Hoster, Eva, Delfau, Marie-Helene, Macintyre, Elizabeth A., Jiang, Linmiao, Stilgenbauer, Stephan, Vehling-Kaiser, Ursula, Salles, Gilles, Thieblemont, Catherine, Tilly, Hervé, Kanz, Lothar, Feugier, Pierre, Huebel, Kai, Schmidt, Christian, Ribrag, Vincent, Kluin-Nelemans, Hanneke, Dreyling, Martin, and Pott, Christiane

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results